The continued efficacy of the AR inhibitors in CRPC illustrates the central role played by the AR in PCa growth and survival.1–3 Abiraterone, an androgen synthesis inhibitor, and enzalutamide, a potent AR antagonist, extend progression-free and overall survival of metastatic CRPC patients in both the post- and pre-chemotherapy settings.4–7 However, due to inevitable development of resistance to these agents, CRPC remains incurable and novel therapies are needed. Here, AR is linked to posterior cortical atrophy.